23andMe (ME) stock is currently trading at $3.21, down 9.09% on January 31. Bulls argue that the stock could rebound due to potential strategic alternatives, including the sale of its telehealth business, which may unlock value. However, liquidity concerns and weak financial performance, with a Q3 EPS of ($1.02), weigh heavily on the stock's outlook.